StockData
SAB Biotherapeutics, Inc. logo

SAB Biotherapeutics, Inc. (SABS) stock

SABSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$3.20+0.25 (+8.47%)

Close on Nov 18, 2026Market cap $291.16MP/E –Yield –

SAB Biotherapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

SAB Biotherapeutics's pe ratio was 13.4× on Apr 30, 2026, against 23.6× a year earlier.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Apr 30, 202613.4×+3.9
2025Dec 31, 20259.5×−4.4
2022Jan 31, 202213.9×−4.8
2021Dec 31, 202118.6×–

More SAB Biotherapeutics figures

See a number that looks wrong?